Rezultati pretrage - Michael McCleod

  • Prikaz rezultata 1 – 9 od 9
Detaljiziraj rezultate
  1. 1
    A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study

    A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study od David Planchard, Takashi Yokoi, Michael McCleod, Jürgen R. Fischer, Young‐Chul Kim, Marc Ballas, Kelvin Shi, Jean‐Charles Soria

    Izdano 2016
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  2. 2
    B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC)

    B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients... od Thomas J. Lynch, Taral Patel, Luke Dreisbach, Michael McCleod, W. Heim, Hermann Robert, Paschold Eugene, Virginie Pautret, Martin R. Weber, Donald Woytowitz

    Izdano 2007
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  3. 3
    Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial

    Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial od Fairooz F. Kabbinavar, Joseph J. Schulz, Michael McCleod, Taral Patel, John Hamm, J. Randolph Hecht, R. Mass, B. Perrou, B. Nelson, William Novotny

    Izdano 2005
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  4. 4
    P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153

    P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153 od David R. Spigel, Lee S. Schwartzberg, David Waterhouse, Jason C. Chandler, Maen Hussein, Robert M. Jotte, Edward J. Stepanski, Michael McCleod, Ray D. Page, Rohini Sen, Jeffrey G. McDonald, Kelly L. Bennett, Beata Korytowsky, Nivedita Aanur, Craig H. Reynolds

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  5. 5
    ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

    ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer od David Planchard, Niels Reinmuth, С. В. Орлов, Jürgen R. Fischer, Shunichi Sugawara, Sławomir Mańdziuk, Diego Márquez-Medina, Silvia Novello, Yuichiro Takeda, Ross A. Soo, K. Park, Michael McCleod, Sarayut Lucien Geater, Mark Powell, R. May, Urban Scheuring, Paul K. Stockman, Dariusz M. Kowalski

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  6. 6
    IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

    IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as firs... od Federico Cappuzzo, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans‐Georg Kopp, Davey B. Daniel, Steve McCune, Tarek Mekhail, Alona Zer, Niels Reinmuth, A. Sadiq, Venice Archer, Tania Ochi Lohmann, L. Wang, Marcin Kowanetz, Wei‐Hsin Lin, A. Sandler, Howard West

    Izdano 2018
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  7. 7
    Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

    Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell... od Ravi Salgia, R Weaver, Michael McCleod, John R. Stille, S. Betty Yan, Stephanie Roberson, John Polzer, Amy Flynt, Eyas Raddad, Victoria L. Peek, Sameera R. Wijayawardana, Suzane L. Um, Steve Gross, Mark C. Connelly, Carrie Morano, Madeline Repollet, Renouard Sanders, Kurt Baeten, David D’Haese, David R. Spigel

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  8. 8
    Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

    Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Age... od David R. Spigel, Michael McCleod, Robert M. Jotte, Lawrence H. Einhorn, Leora Horn, David Waterhouse, Ben Creelan, Sunil Babu, Natasha B. Leighl, Jason C. Chandler, Félix Couture, George P. Keogh, Glenwood Goss, Davey B. Daniel, Edward B. Garon, Lee S. Schwartzberg, Rohini Sen, Beata Korytowsky, Ang Li, Nivedita Aanur, Maen Hussein

    Izdano 2019
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  9. 9
    Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

    Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153 od David Waterhouse, Edward B. Garon, Jason C. Chandler, Michael McCleod, Maen Hussein, Robert M. Jotte, Leora Horn, Davey B. Daniel, George P. Keogh, Ben Creelan, Lawrence H. Einhorn, Justin Baker, Samer S. Kasbari, Petros Nikolinakos, Sunil Babu, Félix Couture, Natasha B. Leighl, Craig H. Reynolds, George R. Blumenschein, Vijay Gunuganti, Ang Li, Nivedita Aanur, David R. Spigel

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: